Relmada Therapeutics Shares Gain on Positive Study Results, Financing Agreement

Dow Jones

03/09

By Connor Hart

Shares of Relmada Therapeutics jumped after the company said its treatment for non-muscle invasive bladder cancer performed well in a recent trial and would be advanced to late-stage testing.

The stock climbed 51%, to $6.70, in premarket trading Monday.

The biotechnology company said before the bell that its treatment, NDV-01, demonstrated a 12-month complete response rate of 76% during a recent mid-stage study, with a favorable safety profile.

"These 12-month data show the potential durability of NDV-01's clinical response profile," said Raj Pruthi, chief medical officer of oncology.

He added that the interim results provide "meaningful clinical validation of the program" and support the treatment's advancement into a late-stage study.

Relmada separately said Monday it has entered a securities purchase agreement for private investment in public equity financing, expected to result in gross proceeds of about $160 million.

The PIPE financing included participation several firms, including Venrock Healthcare Capital Partners, Commodore Capital and Janus Henderson Investors.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

March 09, 2026 08:30 ET (12:30 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2618626398"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618626398\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618626398?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618626398","market":"us","top_or_hot":-1,"title":"Relmada Therapeutics Shares Gain on Positive Study Results, Financing Agreement","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> jumped after the company said its treatment for non-muscle invasive bladder cancer performed well in a recent trial and would be advanced to late-stage testing. \n</p>\n<p>\n  The stock climbed 51%, to $6.70, in premarket trading Monday. \n</p>\n<p>\n  The biotechnology company said before the bell that its treatment, NDV-01, demonstrated a 12-month complete response rate of 76% during a recent mid-stage study, with a favorable safety profile. \n</p>\n<p>\n  \"These 12-month data show the potential durability of NDV-01's clinical response profile,\" said Raj Pruthi, chief medical officer of oncology. \n</p>\n<p>\n  He added that the interim results provide \"meaningful clinical validation of the program\" and support the treatment's advancement into a late-stage study. \n</p>\n<p>\n  Relmada separately said Monday it has entered a securities purchase agreement for private investment in public equity financing, expected to result in gross proceeds of about $160 million. \n</p>\n<p>\n  The PIPE financing included participation several firms, including Venrock Healthcare Capital Partners, Commodore Capital and <a href=\"https://laohu8.com/S/JHG\">Janus Henderson</a> Investors. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 08:30 ET (12:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Relmada Therapeutics Shares Gain on Positive Study Results, Financing Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRelmada Therapeutics Shares Gain on Positive Study Results, Financing Agreement\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-03-09 20:30</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> jumped after the company said its treatment for non-muscle invasive bladder cancer performed well in a recent trial and would be advanced to late-stage testing. \n</p>\n<p>\n  The stock climbed 51%, to $6.70, in premarket trading Monday. \n</p>\n<p>\n  The biotechnology company said before the bell that its treatment, NDV-01, demonstrated a 12-month complete response rate of 76% during a recent mid-stage study, with a favorable safety profile. \n</p>\n<p>\n  \"These 12-month data show the potential durability of NDV-01's clinical response profile,\" said Raj Pruthi, chief medical officer of oncology. \n</p>\n<p>\n  He added that the interim results provide \"meaningful clinical validation of the program\" and support the treatment's advancement into a late-stage study. \n</p>\n<p>\n  Relmada separately said Monday it has entered a securities purchase agreement for private investment in public equity financing, expected to result in gross proceeds of about $160 million. \n</p>\n<p>\n  The PIPE financing included participation several firms, including Venrock Healthcare Capital Partners, Commodore Capital and <a href=\"https://laohu8.com/S/JHG\">Janus Henderson</a> Investors. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 08:30 ET (12:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2618626398","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618626398","pubTimestamp":1773059400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Relmada Therapeutics jumped after the company said its treatment for non-muscle invasive bladder cancer performed well in a recent trial and would be advanced to late-stage testing.The stock climbed 51%, to $6.70, in premarket trading Monday.The biotechnology company said before the bell that its treatment, NDV-01, demonstrated a 12-month complete response rate of 76% during a recent mid-stage study, with a favorable safety profile.\"These 12-month data show the potential durability of NDV-01's clinical response profile,\" said Raj Pruthi, chief medical officer of oncology.He added that the interim results provide \"meaningful clinical validation of the program\" and support the treatment's advancement into a late-stage study.Relmada separately said Monday it has entered a securities purchase agreement for private investment in public equity financing, expected to result in gross proceeds of about $160 million.The PIPE financing included participation several firms, including Ven","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","RLMD":"Relmada Therapeutics, Inc.","BK4539":"次新股","LENZ":"Therapeutics","BK4139":"生物科技"},"translate_title":"Relmada Therapeutics股价因积极的研究结果和融资协议而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"RLMD":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Relmada Therapeutics jumped after the company said its treatment for non-muscle invasive bladder cancer performed well in a recent trial and would be advanced to late-stage testing. \n\n\n  The stock climbed 51%, to $6.70, in premarket trading Monday. \n\n\n  The biotechnology company said before the bell that its treatment, NDV-01, demonstrated a 12-month complete response rate of 76% during a recent mid-stage study, with a favorable safety profile. \n\n\n  \"These 12-month data show the potential durability of NDV-01's clinical response profile,\" said Raj Pruthi, chief medical officer of oncology. \n\n\n  He added that the interim results provide \"meaningful clinical validation of the program\" and support the treatment's advancement into a late-stage study. \n\n\n  Relmada separately said Monday it has entered a securities purchase agreement for private investment in public equity financing, expected to result in gross proceeds of about $160 million. \n\n\n  The PIPE financing included participation several firms, including Venrock Healthcare Capital Partners, Commodore Capital and Janus Henderson Investors. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 08:30 ET (12:30 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}